Litcius/Paper detail

Upadacitinib in Patients With Difficult-to-Treat Crohn’s Disease

Cristina Bezzio, Gianluca Franchellucci, Edoardo Savarino, Mauro Mastronardi, Flavio Andrea Caprioli, Giorgia Bodini, Angela Variola, Franco Scaldaferri, Federica Furfaro, Emma Calabrese, Mariabeatrice Principi, Giuseppe Biscaglia, Manuela Marzo, Andrea Michielan, Carolina Aliai Micol Cavalli, Annalisa Aratari, Michele Campigotto, Linda Ceccarelli, Maria Cappello, Simone Saibeni, Paola Balestrieri, Alessandra Soriano, Valentina Casini, Lorenzo Bertani, Brigida Barberio, Francesco Conforti, Silvio Danese, Alessandro Armuzzi

2024Crohn s & Colitis 36012 citationsDOIOpen Access PDF

Abstract

Lay Summary Upadacitinib has recently been approved for treating Crohn’s disease (CD). Here, we report on the effectiveness and safety of upadacitinib in a cohort of patients with difficult-to-treat CD being cared for at clinical centers across Italy.

Topics & Concepts

MedicineCrohn's diseaseCohortDiseaseInternal medicineIntensive care medicineInflammatory Bowel DiseaseMicroscopic ColitisAutoimmune and Inflammatory Disorders